DXC Technology (NYSE:DXC) executives used the company’s fiscal third-quarter 2026 earnings call to outline progress on a ...
Optiscan has made key progress in the December quarter with multiple clinical studies advancing to support US FDA submissions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results